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Abstract Inositol phosphorylceramide synthase (IPC synthase)
is an essential and unique enzyme in fungal sphingolipid
biosynthesis and is the target of the cyclic nonadepsipeptide
antibiotic aureobasidin A. As a first step towards understanding
the mechanism of aureobasidin A inhibition, we developed a
fluorometric HPLC assay for IPC synthase using the Saccha-
romyces cerevisiae enzyme and the fluorescent substrate analog
6-[N-(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-hexanoyl ceram-
ide (C6-NBD-cer). The kinetic parameters for C6-NBD-cer were
comparable to those for the synthetic substrate N-acetyl-
sphinganine used previously. Aureobasidin A acted as a tight-
binding, non-competitive inhibitor with respect to C6-NBD-cer
and had a Ki of 0.55 nM.
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1. Introduction
Sphingolipids are essential membrane components in both
mammalian and fungal cells and share their biosynthetic path-
way up to the formation of sphinganine [1] (Fig. 1). Subse-
quent to sphinganine formation, the mammalian and fungal
pathways diverge. In mammalian cells, ceramide gives rise to
a host of sphingolipids: sphingomyelin, cerebrosides and gan-
gliosides. In fungi, phytoceramide gives rise mostly to inositol-
containing sphingolipids: inositol phosphorylceramide (IPC),
mannose-IPC (MIPC) and inositol phosphoryl-MIPC
(M(IP)2C) [1]. The ¢rst post-ceramide step is catalyzed by
IPC synthase and involves the transfer of the phosphoinositol
group from phosphatidylinositol (PI) to the 1-hydroxy group
of phytoceramide to form IPC [1]. Recent studies have shown
IPC synthase to be essential for fungal growth and to be the
target of the antifungal aureobasidin A [2]. In addition to
aureobasidin A [3^6], IPC synthase is inhibited by two struc-
turally distinct natural products that also have antifungal ac-
tivity: the lipid-like khafrefungin [7] and the macrolide galbo-
nolide [8,9]. All three compounds inhibit IPC synthase activity
at (sub)nanomolar concentrations. Their interaction with the
enzyme has obvious implications for antifungal drug design.
IPC synthase activity can be assayed using radiolabeled N-
acetylsphinganine (C2-cer) [2] or radiolabeled PI [10]. In both
assay methods, the IPC product is separated from the sub-
strate by solvent extraction (in the case of radiolabeled PI-
based assay after mild alkaline hydrolysis). Both methods
generate substantial amounts of radioactive waste and neither
method is adequate for the large number of assays necessary
for detailed inhibition studies. We therefore examined the
suitability of a £uorescent analog of ceramide as a substrate
and developed an HPLC-based £uorometric assay. The assay
enabled us to examine the inhibition kinetics of aureobasidin
A with IPC synthase of Saccharomyces cerevisiae. The results
are described in this paper.
2. Materials and methods
2.1. Materials
S. cerevisiae W303 (MATa, ura3, leu2, his3, ade2, trp1) was from
the DuPont Pharmaceuticals Culture Collection. Tris base, CHAPS,
and dimethylsulfoxide (DMSO) were purchased from Sigma Chemical
Co; 6-[N-(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-hexanoyl ceramide
(C6-NBD-cer) (Fig. 2) was from Matreya Inc.; PI was from Avanti
Polar Lipids; aureobasidin A was from Panvera Corp.; acetic acid
(CH3COOH) and acetonitrile (CH3CN) (HPLC grade) were from J.T.
Baker. All other reagents were of the highest grade available commer-
cially.
HPLC measurements were performed with a Waters 2690 Alliance
System using a C18 reversed-phase column (ZOBAX, 25 cmU4.6 mm
i.d., 5 Wm, Hewlett Packard).
2.2. IPC synthase activity assay
Typically, C6-NBD-cer (stock solution, 2 mM in DMSO; assay
concentration, 0.1 mM) and PI (stock solution, 10 mM in assay bu¡-
er; assay concentration, 2 mM) were added to assay bu¡er (50 mM
Tris^HCl, pH 7.0, 10 mM EDTA, 150 mM NaCl, 10% glycerol, 2 mM
CHAPS) and the reaction was initiated by the addition of microsomal
membranes (prepared by a slight modi¢cation of a published proce-
dure [11]; ¢nal protein concentration 0.1 mg/ml). The reaction mix-
ture (total volume 50 Wl) was incubated at 30‡C for various times and
the reaction was quenched with 10% acetic acid. After centrifugation
at 10 000Ug for 3 min, a 10^20 Wl aliquot of the supernatant was
injected with an automatic sample injector into an HPLC instrument.
Fluorescent substrate and product (Vex = 465 nm, Vem = 530 nm) were
separated on a C18 reversed-phase column with a gradient of 50%
CH3CN^50% H2O (0.1% CH3COOH) to 90% CH3CN^10% H2O
(0.1% CH3COOH) at a £ow rate of 1 ml/min and quantitated by
integrating the peak areas. The gradient was stable for about 60 cycles,
after which period the column was washed with 100% CH3CN. Frac-
tions from the two HPLC peaks with retention times of 5.2 and 12.2
min respectively were collected. After evaporating the solvent, samples
were analyzed by electrospray LC/MS and MS/MS using a Micromass
Q-TOF hybrid mass spectrometer operated in the positive ion electro-
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spray mode with an HP1100 liquid chromatograph and autosam-
pler.
In preliminary experiments, the linear range of IPC product forma-
tion as a function of protein concentration was determined. Assay
mixtures contained a ¢xed concentration of substrates (2 mM PI
(four times the apparent Km) and 0.1 mM C6-NBD-cer) and samples
were incubated for a ¢xed time (20 min). The linear range of IPC
product formation was then determined as a function of incubation
time. Assay mixtures contained a ¢xed concentration of substrates
(2 mM PI and 0.005 mM C6-NBD-cer) and 0.1 mg/ml of membrane
protein.
The initial velocity of IPC synthase was next determined at di¡erent
concentrations of C6-NBD-cer with a ¢xed PI concentration of 2 mM
and membrane protein concentration of 0.1 mg/ml. Data were plotted
and ¢tted to the Michaelis^Menten equation using the Kaleidagraph
¢tting program (Synergy Software) and Km and Vmax were deter-
mined.
2.3. Inhibition by aureobasidin A
To investigate the mechanism of aureobasidin A inhibition, the IPC
synthase concentration was determined ¢rst at a protein concentration
of 1.0 mg/ml and C6-NBD-cer concentration of 10 WM. Various au-
reobasidin A concentrations (19.8^0.5 nM; stock solution, 1 mM in
DMSO) were preincubated with microsomal membranes for 5 min
prior to the addition of substrates. IPC product formation was sub-
sequently analyzed by HPLC and the fractional velocity of the reac-
tion was plotted as a function of inhibitor concentrations. The curve
was ¢tted to Eq. 1, allowing both [Et] and Kiÿapp to £oat [12,13]. A
value of 5.6 nM for [Et] was thus obtained. To determine the inhib-
ition pattern of IPC synthase by aureobasidin A, the above measure-
ments were repeated at various substrate concentrations (2.5^80 WM)
using a diluted protein concentration of 0.1 mg/ml (corresponding to
[Et] of 0.56 nM). Under these assay conditions, the values of Kiÿapp
and [Et] are close together and error in the estimation of [Et] can have
a signi¢cant e¡ect on the estimation of Kiÿapp. [Et] was therefore ¢xed
at 0.56 nM to examine the dependence of Kiÿapp as a function of C6-
NBD-cer concentration. Data were ¢tted to Eq. 1 and Kiÿapp was
calculated and plotted as a function of substrate concentration.
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3. Results and discussion
The recent emergence of IPC synthase as an essential and
unique fungal enzyme has provided a new target for antifun-
gal drug discovery. The absence of a mammalian counterpart
reduces the odds for mechanism-associated host toxicity. Fur-
ther, blocking this step not only depletes the fungal cell of
essential sphingolipids but also causes accumulation of ceram-
ide, known to induce apoptosis in mammalian cells [14,15].
The fungicidal action of aureobasidin A, a feature highly de-
sirable for the treatment of opportunistic fungal infections,
has been suggested to be due to ceramide accumulation [6].
Signi¢cantly, the IPC synthase (AUR1) gene has been identi-
¢ed in a wide range of fungi including two key opportunistic
human pathogens: Candida albicans and Aspergillus fumigatus
[16]. Thus, IPC synthase inhibitors are potentially broad-spec-
trum antifungals.
Although the essential role of IPC synthase has been ¢rmly
established, its interactions with substrates and inhibitors have
not been fully investigated. To facilitate this task, we devel-
oped a £uorometric HPLC assay based on an analog of phy-
toceramide, C6-NBD-cer. This analog has been successfully
employed previously to study the intracellular transport and
metabolism of dihydroceramide, an intermediate in mamma-
lian sphingolipid synthesis [17^20].
3.1. IPC synthase activity assay
The IPC synthase reaction with C6-NBD-cer is shown in
Fig. 2. The mass spectra of the two £uorescent peaks on the
HPLC trace of the reaction mixture displayed (M+H) at m/z
576 (12.2 min HPLC peak) and at m/z 818 (5.2 min HPLC
peak). The former corresponds to the predicted mass of the
C6-NBD-cer substrate and the latter to the predicted mass of
the C6-NBD^IPC product. In addition, the MS/MS spectrum
of m/z 818 showed a fragment ion at m/z 547, corresponding
to the loss of the phosphoinositol head group and providing
further structural evidence for the identity of the 5.2 min peak
as C6-NBD^IPC. The peak area of the C6-NBD^IPC product
had a detection limit of 0.1 pmol and was linear with product
concentration up to at least 25 pmol.
IPC synthase activity was linear with incubation time at
least up to 30 min and with protein concentration up to
2 mg/ml (data not shown). All subsequent studies were per-
formed within the linear range.
Initial velocities of the IPC synthase reaction were next
measured at various C6-NBD-cer concentrations (2.5^80
WM) with a ¢xed PI concentration of 2 mM (Km = 0.5 mM)
and an enzyme concentration of 0.1 mg/ml. Data were ¢tted
to the Michaelis^Menten equation and the apparent Km and
Vmax were estimated to be 9.8 þ 0.1 WM and 0.50 þ 0.02 nmol/
min/mg of protein respectively (Fig. 3). These compare favor-
ably with the Km and Vmax values for the radiolabeled C2-cer
substrate [2], estimated to be 30 WM and 0.26 nmol/min/mg of
protein respectively (M. Je¡ries and N.H. Georgopapadakou,
unpublished data). The attractive kinetic parameters of the
C6-NBD-cer, together with the high sensitivity of C6-NBD^
Fig. 1. Sphingolipid biosynthesis in animals and yeast. Abbrevia-
tions: DAG, diacylglycerol; MIPC, mannose inositol phosphoryl-
ceramide; M(IP)2C, mannose (inositol phosphoryl)2-ceramide.
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IPC detection, make the £uorometric assay more suitable than
the radiochemical assay for inhibition studies, where detection
of low product levels is necessary.
3.2. Inhibition by aureobasidin A
The activity of IPC synthase was measured in the presence
of various aureobasidin concentrations. Microsomal enzyme
was preincubated with aureobasidin A for 5 min before the
addition of the two substrates to allow for completion of any
slow-binding phase and the reaction was initiated by the ad-
dition of PI and C6-NBD-cer. A ¢xed PI concentration of
2 mM and a range of C6-NBD-cer concentrations (2.5^80
WM) were employed. The plot of fractional velocity as a func-
tion of inhibitor concentration (Fig. 4) strongly suggested that
aureobasidin A acts as a tight-binding inhibitor of IPC syn-
thase with an apparent Ki in the subnanomolar range. With
tight-binding inhibitors, where Kiÿapp is at or lower than [Et],
the Henri^Michaelis^Menten equations are not adequate
(since they assume KiÿappD[Et]) and the Morrison equation
[12,13] (Eq. 1) is used to determine Ki values. Therefore, the
data were ¢tted using Morrison’s equation and Kiÿapp at var-
ious substrate concentrations was obtained. The behavior of
Kiÿapp as a function of substrate concentration is diagnostic of
competitive, uncompetitive, or non-competitive inhibition
with respect to the varied substrate. The data in Fig. 4
show that Kiÿapp is independent of the concentration of C6-
NBD-cer (above and below the Km) implying non-competitive
inhibition (i.e. Ki = Kiÿapp). This ¢nding, along with evidence
that aureobasidin A inhibits IPC synthase activity in a variety
of fungi, including C. albicans and A. fumigatus [21], suggests
that aureobasidin A may bind to a distinct, hydrophobic site
on IPC synthase that is conserved among di¡erent fungal
species.
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